There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on G1 Therapeutics Inc (NASDAQ:GTHX) and CytomX Therapeutics Inc (NASDAQ:CTMX) with bullish sentiments.
G1 Therapeutics Inc (GTHX)
In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on G1 Therapeutics Inc. The company’s shares opened today at $53.73, close to its 52-week high of $58.52.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 10.1% and a 42.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and United Therapeutics.
G1 Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $60.33, representing a 12.3% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $61 price target.
.
See today’s analyst top recommended stocks >>
CytomX Therapeutics Inc (CTMX)
In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on CytomX Therapeutics Inc. The company’s shares opened today at $24.77.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.6% and a 47.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
CytomX Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
